Showing 828 results
-
Media Release /East Hanover, NJ, January 10, 2011 – Novartis Pharmaceuticals Corporation (Novartis) has become aware of a United States market recall of all lots of alcohol prep pads, swabs and swabsticks…
-
Media Release /Two pivotal Phase III studies showed ACZ885 may meet significant unmet need for patients for whom many standard therapies are inadequate or inappropriate1,2Regulatory filings for the use of ACZ885 in…
-
Media Release /New professional cycling team, called NOW and Novartis for MS, to compete nationally and ride tandem with MS patients in National MS Society’s bike rides Program kicks-off on the eve of World MS Day…
-
Media Release /- Data show Afinitor delays tumor growth and reduces risk of disease progression in patients with advanced neuroendocrine tumors (NET) of pancreatic origin(1)- Afinitor represents a new approach to…
-
Media Release /- ACZ885, which neutralizes key inflammatory driver interleukin-1 beta[1], provided significant symptom improvement vs. placebo in Phase III pivotal trial[2]- Systemic juvenile idiopathic arthritis…
-
Media Release /- Gilenya-treated patients had fewer T1 gadolinium (Gd)- enhancing lesions versus those treated with interferon beta-1a IM at 12 months and placebo at 24 months - More than 11,000 people in U.S. have…
-
Media Release /Arcapta is the only once-daily long-acting beta2-agonist (LABA) approved in US for maintenance treatment of airflow obstruction in patients with COPDClinical studies with Arcapta showed sustained…
-
Media Release /-- Everolimus combined with hormonal therapy more than doubled time without tumor growth and reduced risk of progression by 57% vs hormonal therapy alone(1)-- Study shows everolimus significantly…
-
Media Release /- Phase III IMPRES study demonstrates potential benefits of QTI571 in patients who remain symptomatic despite treatment with two or more PAH therapies(1)- Evidence indicates that QTI571 targets an…
-
Media Release /- Study met primary endpoint of kidney tumor response rate with 42% of patients on everolimus experiencing a response versus 0% on placebo(1)- Kidney tumors are present in up to 80% of patients with…
